European Real-Life Experience Of Omalizumab (Xolair) And Maintenance Oral Corticosteroid Use In Patients With Severe Persistent Allergic Asthma

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.

SummarySevere persistent asthma causes a substantial morbidity and mortality burden and is frequently inadequately controlled despite intensive guideline-based therapy. Targeting allergic inflammatory processes that underlie the pathogenesis of severe persistent asthma improves asthma control in a significant proportion of patients. Omalizumab, a humanized monoclonal anti-immunoglobulin E (IgE) antibody, has been developed to target IgE, which is central to triggering and maintaining allergic airway inflammation. In a comprehensive program of clinical trials, omalizumab has been shown to reduce asthma exacerbation and emergency visit rates, and to improve quality of life in patients with se…

Corrigendum to “The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update” [Respiratory Medicine 103 (2009) 1098–1113]

a Infection, Inflammation and Repair Division, School of Medicine, University of Southampton, D level Centre Block (MP810), Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK Mainz University Hospital, 55131 Mainz, Germany Hopital Arnaud de Villeneuve, FR-34000 Montpellier, France Novartis Horsham Research Centre, Horsham, RH12 5AB, UK Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA